$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000158364818000074 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$4.910M	$8.345M	$3.927M
YoY Change	-72.95%	112.5%	400.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.560M	$4.750M	$2.850M
YoY Change	-28.64%	66.67%	21.79%
% of Gross Profit
Research & Development	$13.00M	$11.40M	$6.259M
YoY Change	146.68%	82.15%	35.42%
% of Gross Profit
Depreciation & Amortization	$160.0K	$130.0K	$60.00K
YoY Change	60.0%	116.67%	-40.0%
% of Gross Profit
Operating Expenses	$17.56M	$16.15M	$9.111M
YoY Change	50.6%	77.25%	30.85%
Operating Profit		-$7.804M	-$5.184M
YoY Change		50.54%	-16.09%
Interest Expense	$470.0K	$504.0K	$0.00
YoY Change	213.33%
% of Operating Profit
Other Income/Expense, Net	$330.0K	$1.147M	-$1.729M
YoY Change	-66.67%	-166.34%	9377.61%
Pretax Income	-$11.85M	-$6.153M	-$6.913M
YoY Change	-255.31%	-10.99%	11.57%
Income Tax	-$160.0K	$0.00	$146.0K
% Of Pretax Income
Net Earnings	-$11.68M	-$6.153M	-$7.059M
YoY Change	-255.94%	-12.83%	13.92%
Net Earnings / Revenue	-237.88%	-73.73%	-179.76%
Basic Earnings Per Share
Diluted Earnings Per Share	-$215.7K	-$113.7K	-$159.0K
COMMON SHARES
Basic Shares Outstanding	54.15M shares	54.03M shares	44.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.1M	$137.3M	$89.90M
YoY Change	76.45%	52.73%	145.63%
Cash & Equivalents	$74.87M	$89.48M	$89.92M
Short-Term Investments	$53.20M	$47.80M
Other Short-Term Assets	$4.600M	$4.200M	$2.800M
YoY Change	187.5%	50.0%	-39.13%
Inventory
Prepaid Expenses
Receivables	$2.701M	$5.338M	$2.537M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$135.4M	$146.8M	$95.28M
YoY Change	50.78%	54.13%	131.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.049M	$4.687M	$3.456M
YoY Change	25.16%	35.64%	41.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change	-100.0%
Other Assets	$910.0K	$121.0K	$129.3K
YoY Change	600.0%	-6.4%	1.29%
Total Long-Term Assets	$5.959M	$4.808M	$3.585M
YoY Change	-57.7%	34.12%	39.2%
TOTAL ASSETS
Total Short-Term Assets	$135.4M	$146.8M	$95.28M
Total Long-Term Assets	$5.959M	$4.808M	$3.585M
Total Assets	$141.3M	$151.7M	$98.86M
YoY Change	36.07%	53.4%	126.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.350M	$2.693M	$2.602M
YoY Change	36.62%	3.51%	-42.18%
Accrued Expenses	$9.114M	$5.981M	$5.100M
YoY Change	47.71%	17.28%	75.96%
Deferred Revenue	$35.61M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$48.08M	$40.59M	$39.04M
YoY Change	5.03%	3.99%	292.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$27.00K	$32.00K	$43.46K
YoY Change	-27.03%	-26.37%	-2.48%
Total Long-Term Liabilities	$27.00K	$32.00K	$43.46K
YoY Change	-27.03%	-26.37%	-2.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.08M	$40.59M	$39.04M
Total Long-Term Liabilities	$27.00K	$32.00K	$43.46K
Total Liabilities	$101.4M	$101.4M	$94.30M
YoY Change	9.8%	7.52%	671.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$147.1M	-$135.4M	-$127.8M
YoY Change	22.24%	5.93%	32.98%
Common Stock	$190.0M	$188.7M	$134.8M
YoY Change	39.15%	39.93%	4.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.94M	$50.26M	$4.558M
YoY Change
Total Liabilities & Shareholders Equity	$141.3M	$151.7M	$98.86M
YoY Change	36.07%	53.4%	126.16%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$11.68M	-$6.153M	-$7.059M
YoY Change	-255.94%	-12.83%	13.92%
Depreciation, Depletion And Amortization	$160.0K	$130.0K	$60.00K
YoY Change	60.0%	116.67%	-40.0%
Cash From Operating Activities	-$9.060M	-$14.36M	$35.20M
YoY Change	92.77%	-140.8%	-1083.24%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	-$320.0K	-$290.0K
YoY Change	-29.63%	10.34%	45.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.650M	$53.72M	$0.00
YoY Change	-89.42%
Cash From Investing Activities	-$5.220M	$53.40M	-$290.0K
YoY Change	-88.34%	-18513.79%	45.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	270.0K	2.030M
YoY Change	-98.33%	-86.7%	-3483.33%
NET CHANGE
Cash From Operating Activities	-9.060M	-14.36M	35.20M
Cash From Investing Activities	-5.220M	53.40M	-290.0K
Cash From Financing Activities	10.00K	270.0K	2.030M
Net Change In Cash	-14.27M	39.31M	36.94M
YoY Change	-70.79%	6.42%	-1061.98%
FREE CASH FLOW
Cash From Operating Activities	-$9.060M	-$14.36M	$35.20M
Capital Expenditures	-$570.0K	-$320.0K	-$290.0K
Free Cash Flow	-$8.490M	-$14.04M	$35.49M
YoY Change	118.25%	-139.56%	-1150.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54149719	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Accelerated Filer
CY2017	pirs	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Income Tax Expense Benefit Before Valuation Allowance Impact TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateIncomeTaxExpenseBenefitBeforeValuationAllowanceImpact	-3700000	USD
CY2017Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6170000	USD
CY2018Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5981000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2452000	USD
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Trading Symbol TradingSymbol	PIRS
CY2017Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	791000	USD
CY2018Q3	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1811000	USD
CY2017Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	424000	USD
CY2018Q3	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	480000	USD
CY2018Q3	pirs	Cash Cash Equivalents And Investments CashCashEquivalentsAndInvestments	137300000	USD
CY2017Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	62851000	USD
CY2018Q3	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	82424000	USD
CY2017Q3	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2018Q3	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	800000	USD
	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	700000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	121000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	222000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2693000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15546000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5338000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6170000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5981000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1322000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1077000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2879000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3299000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4695000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3053000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	136484000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188644000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
CY2017Q4	us-gaap	Assets Assets	103876000	USD
CY2018Q3	us-gaap	Assets Assets	151657000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	89790000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	146849000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	326000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	49000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	47545000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	47822000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29356000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89921000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37878000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89482000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7454000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26124000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	60565000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	51604000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45017062	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54149719	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45017062	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54149719	shares
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6632000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13430000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37153000	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31920000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	46542000	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	60770000	USD
	us-gaap	Depreciation Depreciation	268000	USD
	us-gaap	Depreciation Depreciation	405000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	3755000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1234000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2325000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1841000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2852000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11190000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4748000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13878000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6913000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24179000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6153000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15220000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	146000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	959000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	902000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-77269000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-19370000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	504000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1491000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	92354000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	101396000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103876000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	9922000	USD
CY2018Q3	us-gaap	Long Term Investments LongTermInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3493000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151657000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45775000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	40594000	USD
CY2017Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	3650000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	6166000	USD
CY2018Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7873000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	22541000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	48504000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1131000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3658000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	54448000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	7992000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-7059000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25138000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6153000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15072000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9111000	USD
	us-gaap	Operating Expenses OperatingExpenses	28205000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	16149000	USD
	us-gaap	Operating Expenses OperatingExpenses	42370000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5184000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21082000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7804000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18183000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1308000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	772000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	121000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-395000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-986000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	27000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	546000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-506000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1096000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-87000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	376000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1729000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3097000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1147000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1472000	USD
CY2017Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	14000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	14000	USD
CY2018Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	91000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	67015000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1131000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1133000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4963	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2907	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4963	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2907	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1615000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4207000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	64490000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	366000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	983000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3127000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	314000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6913000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7986000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4034000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4687000	USD
CY2017Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	263000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	943000	USD
CY2018Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	472000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1555000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6259000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17015000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11401000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44387000	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28492000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120312000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135384000	USD
CY2017Q3	us-gaap	Revenues Revenues	3927000	USD
	us-gaap	Revenues Revenues	7123000	USD
CY2018Q3	us-gaap	Revenues Revenues	8345000	USD
	us-gaap	Revenues Revenues	24187000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
	us-gaap	Share Based Compensation ShareBasedCompensation	1962000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3665000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9975000	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	34751000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	47822000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	50261000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1096000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43624000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54089000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52721000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments, and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments, and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-18-000074-index-headers.html	Edgar Link	pending
0001583648-18-000074-index.html	Edgar Link	pending
0001583648-18-000074.txt	Edgar Link	pending
0001583648-18-000074-xbrl.zip	Edgar Link	pending
exhibit311q3.htm	Edgar Link	pending
exhibit312q3.htm	Edgar Link	pending
exhibit321q3.htm	Edgar Link	pending
exhibit322q3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20180930.xml	Edgar Link	completed
pirs-20180930.xsd	Edgar Link	pending
pirs-20180930_cal.xml	Edgar Link	unprocessable
pirs-20180930_def.xml	Edgar Link	unprocessable
pirs-20180930_lab.xml	Edgar Link	unprocessable
pirs-20180930_pre.xml	Edgar Link	unprocessable
pirs9-30x201810xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2018 Q4 Form 10-Q Financial Statement

#000158364818000074 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2018 Q4 Form 10-Q Financial Statement

#000158364818000074 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs